Allarity Therapeutics, Inc. Derivative Credit Risk Valuation Adjustment, Derivative Liabilities
Allarity Therapeutics, Inc. (ALLR) had Derivative Credit Risk Valuation Adjustment, Derivative Liabilities of $7.18 million as of 2021-12-31, per its 10-K filed 2023-03-13.
Discontinued › Notes › Derivative Instruments and Hedging Activities › Derivative Instrument Detail
us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities · last filed 2023-03-13
- 2021-12-31: Derivative Credit Risk Valuation Adjustment, Derivative Liabilities $7.18M.
| Period end | Derivative Credit Risk Valuation Adjustment, Derivative Liabilities |
|---|---|
| 2021-12-31 | $7.18M 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |